A phase II trial enrolling 117 multi-refractory cHL patients previously exposed to both BV and anti-PD-1 confirmed the encouraging efficacy of cami-T in this challenging setting. This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.